Ultragenyx Pharmaceutical | RARE - Trade Creditors


Ultragenyx Pharmaceutical reported $40.57M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Esperion Therapeutics USD 77.51M 2.81M Sep/2025
Immunic USD 7.92M 25K Sep/2025
Insmed USD 79.91M 316K Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Karyopharm Therapeutics USD 5.39M 2.8M Sep/2025
Kyowa Hakko Kirin JPY 125.04B 1.32B Dec/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Moderna USD 317M 50M Dec/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025
Xoma USD 2.65M 1.52M Sep/2025